Abstract Search

ea0063p619 | Diabetes, Obesity and Metabolism 2 | ECE2019

Trial-in-progress: ZEPHYR, a pivotal phase 2b/3 randomized, placebo-controlled study of livoletide, a novel unacylated ghrelin analog, for the treatment of hyperphagia and food-related behaviors in patients with Prader-Willi syndrome

Allas Soraya , Mohideen Pharis , Delale Thomas , Lin Vivian , Yeh Michael , Tremel Nadege , Tauber Maithe

Background: Prader-Willi syndrome (PWS) is a rare disease characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to a significant burden on patients and caregivers. There is no approved treatment for hyperphagia in PWS. Patients with PWS have increased circulating levels of the orexigenic hormone acylated ghrelin (AG) with a relative deficit of unacylated ghrelin (UAG). Livoletide (AZP-531) is a first-in-cla...

shares

ea0063p621 | Diabetes, Obesity and Metabolism 2 | ECE2019

Nonclinical development of livoletide (AZP-531), a peptide analog of unacylated ghrelin for the treatment of hyperphagia in Prader-Willi syndrome

Milano Stephane , Allas Soraya , Cade Didier , Briffaux Jean-Paul , Spencer Andrew

Prader-Willi syndrome (PWS) is a rare complex endocrine disease characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to a significant burden on patients and caregivers. There are no approved treatments for hyperphagia in PWS. Patients with PWS have increased circulating levels of the orexigenic hormone acylated ghrelin (AG) with a relative deficit of unacylated ghrelin (UAG). These abnormalities in AG and ...

shares

ea0073oc6.5 | Oral Communications 6: Calcium and Bone | ECE2021

Safety, tolerability and pharmacodynamics of AZP-3601, a novel long-acting PTH analog, in healthy adults: Data from a randomized, double-blind, placebo-controlled phase 1 study

Allas Soraya , Ovize Michel , Culler Michael D. , Geraul Clarisse , Jeroen van de Wetering , Mannstadt Michael

Hypoparathyroidism is a rare disease characterized by a deficiency in parathyroid hormone (PTH) that results in hypocalcemia and hyperphosphatemia. Current treatment approaches, including high dose oral calcium and active vitamin D, as well as recombinant human PTH (1–84), do not provide adequate or consistent control of either serum calcium or clinical symptoms over a full 24-hour period. AZP-3601 is a novel 36 amino-acid PTH analog that has been designed to potently bi...

shares

ea0073aep644 | Thyroid | ECE2021

Assessment of clinical burden and practice patterns in patients with chronic hypoparathyroidism in the united states (us): a claims data analysis using diagnosis-based criteria

Sharma Dolly , L Deering Kathleen , Allas Soraya , Culler Michael D. , Loustau Patrick , Weiss Blandine , Michelle Mitchell Deborah , Astolfi Danette , Mannstadt Michael

ObjectivesThere is a paucity of real-world studies analyzing comorbidities, lab testing and treatment patterns of patients with chronic hypoparathyroidism (cHP). This study describes a large cohort of cHP patients identified using a diagnosis-based approach from a US claims database.MethodsThis retrospective study was conducted using a large (130 million individuals) claims database (HealthVerity Closed Payer...

shares

ea0073ep226 | Thyroid | ECE2021

Assessment of clinical burden and practice patterns in patients with chronic hypoparathyroidism in the United States (US): A claims data analysis using a surgery-based approach

Sharma Dolly , L Deering Kathleen , Loustau Patrick , Michael D. Culler , Allas Soraya , Weiss Blandine , Michelle Mitchell Deborah , Astolfi Danette , Mannstadt Michael

ObjectivesThere is a paucity of real-world studies on the clinical burden and practice patterns associated with chronic hypoparathyroidism (cHP). This study assesses the comorbidities, treatment and lab testing patterns in cHP patients identified using surgery-based criteria.MethodsThis was a retrospective study conducted using a large (130 million individuals) US claims database (HealthVerity Closed Payer Cl...

shares

Endocrine Abstracts

Trial-in-progress: ZEPHYR, a pivotal phase 2b/3 randomized, placebo-controlled study of livoletide, a novel unacylated ghrelin analog, for the treatment of hyperphagia and food-related behaviors in patients with Prader-Willi syndrome

Nonclinical development of livoletide (AZP-531), a peptide analog of unacylated ghrelin for the treatment of hyperphagia in Prader-Willi syndrome

Safety, tolerability and pharmacodynamics of AZP-3601, a novel long-acting PTH analog, in healthy adults: Data from a randomized, double-blind, placebo-controlled phase 1 study

Assessment of clinical burden and practice patterns in patients with chronic hypoparathyroidism in the united states (us): a claims data analysis using diagnosis-based criteria

Assessment of clinical burden and practice patterns in patients with chronic hypoparathyroidism in the United States (US): A claims data analysis using a surgery-based approach

BiosciAbstracts